

KLOTO-DX



THE PROBLEM

Sepsis, a systemic infection characterized by the presence of bacteria in the bloodstream of the patient, is one of the leading causes of intrahospitality death.

- 31,5M people per year affected worldwide (lethal in 17-30% of cases)
- Mortality increase 7% for every hour the patient remains without a proper treatment (blood culture results take between 1-5 days)
- High costs for the public health system (900M € per year in Spain)

THE SOLUTION

Integration of synthetic biology technology in a portable device that makes a fast, efficient and cost-effective detection and characterization of sepsis-causing bacteria possible.

- Easily used in near-patient setting (primary care, emergency units, field hospitals) to accelerate and improve healthcare professionals decisions.
- Early diagnosis could avoid 80% of deaths and save more than 10k € per patient.

THE PRODUCT

KLOTO-DX is a fully automated and portable molecular diagnostic platform powered by our Plug and Play RNA technology.

- It delivers a multiplexed colorimetric assay visible at naked eye for the detection of sepsis-causing pathogens and their antibiotic resistances.
- Our diagnostic platform detects specific bacterial infections in less than 3 hours, using directly a non-cultured sample of blood from the patient and a low-cost disposable diagnostic kit / cartridge.

MILESTONES

- Founded 2016
- Pre-seed Round 2017: 300k €
- Proof of Concept 2015
- SME instrument 2018
- European Patent Protection 2018
- Final Prototype 2020
- CE Mark/ Market Launch 2019-2020

POTENTIAL MARKET

World blood culture test market: **2,5 Billion (2022)**
 Viral infections and oncology diagnostics: **14 Billion (2022)**
 CAGR: 7,8%
USA 2,5M kits/yr
Europe 3,8M kits/yr
Iberia 420k kits/yr

FUNDING GOALS




- 40% Prototype Scale
- 25% Anal. & preclinic
- 10% IP Protection

KEY METRICS

- 120 €** Price/test
- 3%** Potential annual penetration rate
- 4,4M €** Projected Gross Annual Revenue in 2024
- 16,5 € Billion/Year** Potential Markets
- 20-50%** Gross Margin
- 1,1M €** Current Valuation in the Market



- www.moirai biodesign.com
- [@moirai biodesign](https://twitter.com/moirai biodesign)
- [Moirai Biodesign](https://www.linkedin.com/company/moirai biodesign)



FOUNDERS



Amadís Pagès
CEO



Ivan Dotu
CTO



Núria Conde
CSO



Daniel Poglajen
Technology VP



www.cimti.cat | info@cimti.cat

PROMOTER



WITH THE SUPPORT OF

